Related Experiment Videos

ALK pERKs up MYCN in neuroblastoma

Sven Lindner1, Anton Henssen2, Kathy Astrahantseff3

  • 1Department of Pediatric Oncology and Hematology, University Children's Hospital Essen, 45122 Essen, Germany. German Cancer Consortium (DKTK), Partner Site Essen/Duesseldorf, 45122 Essen, Germany. Department of Translational Neuro-Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Hufelandstr.55, 45122 Essen, Germany. German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Centre for Medical Biotechnology, University Duisburg-Essen, 45122 Essen, Germany.

Science Signaling
|October 30, 2014
PubMed

Insights

Anaplastic lymphoma kinase (ALK) drives neuroblastoma by boosting MYCN expression via extracellular signal-regulated kinase 5 (ERK5). Inhibiting both ALK and ERK5 shows promise for treating this deadly childhood cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Anaplastic lymphoma kinase (ALK) mutations are implicated in various cancers.
  • Crizotinib, an ALK inhibitor, has limited efficacy in MYCN-amplified, ALK-mutant neuroblastoma.
  • Neuroblastoma is a deadly childhood cancer with poor prognosis in certain genetic subtypes.

Purpose of the Study:

  • To identify the molecular mechanisms by which ALK promotes neuroblastoma.
  • To investigate the role of extracellular signal-regulated kinase 5 (ERK5) in ALK-driven neuroblastoma.
  • To evaluate the therapeutic potential of combined ALK and ERK5 inhibition.

Main Methods:

  • Investigated the interaction between ALK and MYCN signaling pathways.
  • Utilized cell viability assays and xenograft tumor models.
  • Assessed the effects of ALK and ERK5 inhibition on neuroblastoma cells.

Main Results:

  • Extracellular signal-regulated kinase 5 (ERK5) acts as a key mediator for ALK to enhance MYCN expression.
  • Combined inhibition of ALK and ERK5 significantly reduced neuroblastoma cell viability in vitro.
  • Dual ALK and ERK5 inhibition demonstrated efficacy in preclinical xenograft tumor models.

Conclusions:

  • ERK5 is a critical downstream effector of ALK in promoting neuroblastoma.
  • Targeting both ALK and ERK5 simultaneously offers a promising therapeutic strategy for neuroblastoma.
  • This approach may also benefit other cancers with MYC(N) overexpression and ALK mutations, such as non-small-cell lung cancer.

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K